PT-141
Bremelanotide (PT-141)
A melanocortin receptor agonist developed from Melanotan II. FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Used off-label for sexual dysfunction in both sexes.
Mechanism of Action
PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, directly stimulating sexual arousal pathways in the brain. Unlike PDE5 inhibitors, it works centrally rather than through vascular mechanisms.
Health Claims & Evidence
Increases sexual desire and arousal
Effective for both male and female sexual dysfunction
Works independently of vascular mechanisms
Short-Term Effects
Increased sexual desire and arousal within 45–60 minutes. Effects last 6–12 hours.
Long-Term Effects
No tolerance development reported. Suitable for as-needed use.
Side Effects
Nausea (most common), flushing, headache, transient blood pressure increase, hyperpigmentation with repeated use.
Contraindications
Avoid with cardiovascular disease or uncontrolled hypertension.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Bremelanotide for hypoactive sexual desire disorder
Clayton et al. · Obstetrics & Gynecology · 2016
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on PT-141 and related peptides, and prepare an educational research summary.
Explore Research